Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RYR2 | Q92736 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910059 | 0.85 | MEN1 (0.53) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL2028082 | 0.80 | — | — | |
| SCHEMBL29364653 | 0.75 | GAA (0.96) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL3556450 | 0.75 | GAA (0.96) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL88911 | 0.75 | GAA (0.96) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL910499 | 0.74 | MEN1 (0.42) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL1147443 | 0.70 | — | — | |
| SCHEMBL3813285 | 0.70 | MEN1 (0.34) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL7998823 | 0.67 | MAOB (0.53) | ALDH1A1GAA | |
| SCHEMBL5759488 | 0.67 | GAA (0.55) | MEN1ALDH1A1GAAKMT2ARYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | claimed |
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| EP-2064213-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008028617-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, PRKACA | MEN1 2591/4885ALDH1A1 1899/4885GAA 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.